SAFETY DATA SHEET



SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

of the mixture

WELLBUTRIN TABLETS

Registration number

Synonyms

WELLUBTRIN TABLETS 75MG * WELLBUTRIN TABLETS 100MG * WELLBUTRIN TABLETAS *

WELLBUTRIN TABLETES * WELLBUTRIN TABLETTA * NDC NO 0173-0177-55 * NDC NO

0173-0178-55 * BUPROPION HYDROCHLORIDE, FORMULATED PRODUCT

Issue date 20-September-2013

Version number

Revision date 20-September-2013 Supersedes date 16-September-2013

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Uses advised against No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK 980 Great West Road

Brentford, Middlesex TW8 9GS UK

UK General Information (normal business hours): +44-20-8047-5000

Email Address: msds@gsk.com Website: www.gsk.com

1.4. Emergency telephone

number

TRANSPORT EMERGENCIES::

UK In-country toll call: +(44)-870-8200418 International toll call: +1 703 527 3887

available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

The mixture has been assessed and/or tested for its physical, health and environmental hazards and the following classification applies.

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Supplemental label information Not applicable.

2.3. Other hazards Caution - Pharmaceutical agent. See section 11 for additional information on health hazards.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

Material name: WELLBUTRIN TABLETS SDS UK **General information**

CAS-No. / EC No. REACH Registration No. INDEX No. Chemical name **Notes**

MICROCRYSTALLINE CELLULOSE 60 - < 709004-34-6

232-674-9

Classification: DSD: -

CLP: -

BUPROPION HYDROCHLORIDE 15 31677-93-7

250-759-9

Classification: **DSD:** Xn;R22, Xi;R36, N;R50-53

CLP: Acute Tox. 4;H302, Eye Irrit. 2;H319, Aquatic Acute 1;H400, Aquatic Chronic 1;H410

Talc 1 - < 3 14807-96-6

238-877-9

Classification: DSD: -

CLP: Carc. 2;H351

Hydrochloric acid 0.14 7647-01-0 #

231-595-7

DSD: C;R35, Xn;R22 Classification:

CLP: Acute Tox. 4;H302, Skin Corr. 1A;H314, Acute Tox. 3;H331, STOT SE 3;H335

Other components below reportable levels 20 - < 30

CLP: Regulation No. 1272/2008.

DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance. PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

The full text for all R- and H-phrases is displayed in section 16. Composition comments

SECTION 4: First aid measures

General information Ensure that medical personnel are aware of the material(s) involved, and take precautions to

protect themselves. Pre-placement and periodic health surveillance is not usually indicated. The final determination of the need for health surveillance should be determined by local risk

assessment.

4.1. Description of first aid measures

Inhalation In case of accident by inhalation: remove casualty to fresh air and keep at rest. If breathing is

difficult, trained personnel should give oxygen. If not breathing, give artificial respiration. Get

medical attention if symptoms occur.

Skin contact Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse.

Get medical attention if symptoms occur.

Eye contact Immediately flush eyes with plenty of water for at least 15 minutes. Get medical attention if

irritation develops and persists.

Ingestion If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large

amount does occur, call a poison control centre immediately.

4.2. Most important symptoms and effects, both acute and

delaved

Irritation of eyes and mucous membranes. The following adverse effects have been noted with therapeutic use of this material: insomnia; agitation; anxiety; headache; tremor; visual disturbances; dry mouth; nausea; vomiting; rash; depression; constipation; convulsions.

4.3. Indication of any immediate medical attention and special treatment needed No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control

information centre.

SECTION 5: Firefighting measures

General fire hazards No unusual fire or explosion hazards noted.

5.1. Extinguishing media

Suitable extinguishing

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

media

Unsuitable extinguishing

media

None known.

Material name: WELLBUTRIN TABLETS

5.2. Special hazards arising from the substance or mixture

During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting procedures

In the event of fire, cool tanks with water spray.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Wear appropriate personal protective equipment. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders

Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the

MSDS.

6.2. Environmental precautions

Avoid release to the environment. Contact local authorities in case of spillage to drain/aquatic environment. Prevent further leakage or spillage if safe to do so. Do not contaminate water. Avoid discharge into drains, water courses or onto the ground.

6.3. Methods and material for containment and cleaning up

Stop the flow of material, if this is without risk. Collect spillage. Prevent product from entering

drains. Following product recovery, flush area with water.

6.4. Reference to other sections

For personal protection, see section 8. For waste disposal, see section 13.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Avoid contact with eyes. Avoid prolonged exposure. Provide adequate ventilation. Wear appropriate personal protective equipment. Observe good industrial hygiene practices. Wash hands thoroughly after handling. Avoid release to the environment. Do not empty into drains.

7.2. Conditions for safe storage, including any incompatibilities

Store locked up. Store in original tightly closed container. Store in a cool, dry place out of direct sunlight. Store away from incompatible materials (see Section 10 of the MSDS).

7.3. Specific end use(s) Medicinal Product

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

GSK

9004-34-6)

Occupational exposure limits

Components	Туре	Value	
BUPROPION HYDROCHLORIDE (CAS 31677-93-7)	8 HR TWA	1000 mcg/m3	
	OHC	2	
MICROCRYSTALLINE CELLULOSE (CAS	OHC	1	

UK, EH40 Workplace Exposure Limits (WELs)

Components	Туре	Value	Form
Hydrochloric acid (CAS 7647-01-0)	STEL	8 mg/m3	Gas and aerosol mists.
•		5 ppm	Gas and aerosol mists.
	TWA	2 mg/m3	Gas and aerosol mists.
		1 ppm	Gas and aerosol mists.
MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)	STEL	20 mg/m3	Inhalable dust.
,	TWA	4 mg/m3	Respirable dust.
		10 mg/m3	Inhalable dust.
Talc (CAS 14807-96-6)	TWA	1 mg/m3	Respirable dust.
ommended monitoring	Follow standard monitoring procedures		

Recommended monitoring

Follow standard monitoring procedures.

procedures

Derived No Effect Level (DNEL) Not available.

Predicted no effect Not available.

concentrations (PNECs)

Material name: WELLBUTRIN TABLETS

8.2. Exposure controls

Appropriate engineering controls

An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level.

Individual protection measures, such as personal protective equipment

General information Personal protection equipment should be chosen according to the CEN standards and in

discussion with the supplier of the personal protective equipment. Follow all local regulations if

personal protective equipment (PPE) is used in the workplace. Eye wash fountain is

recommended.

Eye/face protection If contact is likely, safety glasses with side shields are recommended. (eg. EN 166)

Skin protection

- Hand protection The choice of an appropriate glove does not only depend on its material but also on other quality

> features and is different from one producer to the other. Glove selection must take into account any solvents and other hazards present. Select suitable chemical resistant protective gloves (EN

374) with a protective index 6 (>480min permeation time).

- Other Not normally needed.

Respiratory protection No personal respiratory protective equipment normally required. Thermal hazards Wear appropriate thermal protective clothing, when necessary.

Hygiene measures An occupational/industrial hygiene monitoring method has been developed for this material. For

advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional. Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing

and protective equipment to remove contaminants.

Environmental exposure controls

Hazard guidance and control recommendations Not available.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state Solid **Form** Tablet. Colour Not available. Odour Not available **Odour threshold** Not available. Not available. pН Melting point/freezing point Not available.

Initial boiling point and boiling

range

Not available.

Flash point Not available. Not available. **Evaporation rate** Flammability (solid, gas) Not available. Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

Flammability limit - upper

Not available.

(%)

Not available. Vapour pressure Vapour density Not available. Relative density Not available. Solubility(ies) Not available. **Partition coefficient** Not available.

(n-octanol/water)

Auto-ignition temperature

Not available.

Decomposition temperatureNot available.ViscosityNot available.Explosive propertiesNot available.Oxidizing propertiesNot available.

9.2. Other informationNo relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

10.2. Chemical stability Material is stable under normal conditions.

10.3. Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

10.4. Conditions to avoid Contact with incompatible materials.10.5. Incompatible materials Strong oxidising agents. Fluorine.

10.6. Hazardous decomposition products

Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

SECTION 11: Toxicological information

General information Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

Ingestion Health injuries are not known or expected under normal use. May be harmful if swallowed.

Inhalation Health injuries are not known or expected under normal use. Inhalation of dusts may cause

respiratory irritation.

Skin contact Health injuries are not known or expected under normal use. Dust or powder may irritate the skin.

Eye contact Health injuries are not known or expected under normal use. Dust or powder may irritate eye

tissue.

Symptoms The following adverse effects have been noted with therapeutic use of this material: insomnia;

agitation; anxiety; headache; tremor; visual disturbances; dry mouth; nausea; vomiting; rash;

depression; constipation; convulsions.

11.1. Information on toxicological effects

Acute toxicity Health injuries are not known or expected under normal use. Adverse effects might occur with

repeated ingestion.

Components Species Test results

BUPROPION HYDROCHLORIDE (CAS 31677-93-7)

Α	C	u	t	е
_	·	•	•	·

Oral

LD50 Mouse 544 - 636 mg/kg
Rat 482 - 607 mg/kg

Chronic

Oral

LOEL Dog 40 mg/kg/day, 52 weeks

Rat 100 mg/kg/day, 104 weeks

25 mg/kg/day, 55 weeks

NOAEL Dog 40 mg/kg/day, 52 weeks

Rat 100, 104 weeks

100 mg/kg/day, 55 weeks

SDS UK

Subacute

Oral

NOAEL Dog 150 mg/kg/day, 47 Day

Subchronic

Oral

NOAEL Rat 450 mg/kg/day, 90 Day

Hydrochloric acid (CAS 7647-01-0)

Acute

Inhalation

LC50 Mouse 1108 ppm, 1 Hours

Rat 3124 ppm, 1 Hours

Material name: WELLBUTRIN TABLETS

Components	Species	Test results
LCL0	Guinea pig	4416 ppm, 30 minutes
	Human	3000 ppb, 5 minutes
		1300 ppm, 30 minutes
	Rabbit	4416 ppm, 30 minutes
NOEL	Human	<= 1.8 ppm, 45 minutes, No effect on respiratory function in asthmatics.
Oral		
LD50	Rabbit	900 mg/kg
	Rat	700 mg/kg
Chronic		
Inhalation		
LOAEL	Rat	10 ppm, 128 weeks
Subacute		
Oral		
LD	Rat	34.1 mg/kg/day, 9 weeks
LOEL	Rat	10.2 mg/kg/day, 9 weeks
Subchronic		
Inhalation		
LOEC	Rat	10 ppm, 3 months, Inflammation of lips and nasal cavity.
NOAEC	Rat	20 ppm, 3 months
MICROCRYSTALLINE CEL	LULOSE (CAS 9004-34-6)	
Acute		
Dermal		
LD50	Rabbit	> 2000 mg/kg
Oral		
LD50	Rat	> 2000 mg/kg

^{*} Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Health injuries are not known or expected under normal use.

Corrosivity

HYDROCHLORIC ACID OECD 404

Result: Corrosive Species: Rabbit Test Duration: 1 Hours

BUPROPION HYDROCHLORIDE OECD 404

Result: Non-irritant Species: Rabbit

Irritation Corrosion - Skin: P.I.I. value

BUPROPION HYDROCHLORIDE 0.5

Serious eye damage/eye

Health injuries are not known or expected under normal use. Dust or powder may irritate eye

tissue.

Eye

irritation

HYDROCHLORIC ACID OECD 405

Result: Corrosive effects/irritation

Species: Rabbit

BUPROPION HYDROCHLORIDE Result: Irritant

Species: Rabbit

Respiratory sensitisation Not available.

Skin sensitisation Health injuries are not known or expected under normal use.

Germ cell mutagenicityNo data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic.

Germ cell mutagenicity

Mutagenicity

HYDROCHLORIC ACID <= 10 mmol/L Chromosomal Aberration Assay In Vitro, CHO

cells, IUCLID Result: positive

BUPROPION HYDROCHLORIDE Ames

Result: negative

Material name: WELLBUTRIN TABLETS

110591 Version No.: 13 Revision date: 20-September-2013 Issue date: 20-September-2013

Mutagenicity

HYDROCHLORIC ACID Ames, IUCLID

Result: negative

E coli Pol-A repair assay, IUCLID

Result: negative

BUPROPION HYDROCHLORIDE L5178Y mouse lymphoma thymidine kinase locus assay

Result: negative

HYDROCHLORIC ACID L5178Y mouse lymphoma thymidine kinase locus assay,

IUCLID

Result: negative

Yeast Mutation Assay, IUCLID

Result: negative

BUPROPION HYDROCHLORIDE in vivo cytogenetics assay

Result: positive Species: Rat

Carcinogenicity Health injuries are not known or expected under normal use.

Contains a material (talc) classified as a carcinogen by external agencies. Carcinogenic activity

was seen in inhalation studies using laboratory animals. High concentrations or doses administered over an extended period of time were required to produce adverse effects.

HYDROCHLORIC ACID 10 ppm Inhalation

Result: negative Species: Rat

Observation Period: 128 months

BUPROPION HYDROCHLORIDE Notes: IUCLID Result: negative

Species: Mouse Result: negative Species: Rat

IARC Monographs. Overall Evaluation of Carcinogenicity

Hydrochloric acid (CAS 7647-01-0)

Talc (CAS 14807-96-6)

3 Not classifiable as to carcinogenicity to humans.

2B Possibly carcinogenic to humans.

3 Not classifiable as to carcinogenicity to humans.

Reproductive toxicityThis product is not expected to cause reproductive or developmental effects.

Reproductive toxicity

Reproductivity
HYDROCHLORIC ACID

302 ppm Embryo-foetal development, IUCLID

Result: Maternal toxicity, resorptions, foetal malformations.

Species: Rat

BUPROPION HYDROCHLORIDE Embryo-foetal development- Oral

Result: Maternal toxicity; adverse foetal effects

Species: Rabbit

Embryo-foetal development- Oral

Result: maternal toxicity

Species: Rat Fertility

Result: No effect

Specific target organ toxicity -

single exposure

None known.

HYDROCHLORIC ACID

Specific target organ toxicity - None known.

repeated exposure

Result: Respiratory irritation/corrosion.

Aspiration hazard

Not available.

Mixture versus substance

information

No information available.

Other information Not available.

SECTION 12: Ecological information

12.1. ToxicityNo information is available about the potential of this product to produce adverse environmental

effects. Contains a substance which causes risk of hazardous effects to the environment.

Components Species Test results

BUPROPION HYDROCHLORIDE (CAS 31677-93-7)

Aquatic Acute

Activated Sludge Respiration

IC50 Residential sludge

> 100 mg/l, 3 hours, Nominal

Material name: WELLBUTRIN TABLETS

Components		Species	Test results
	NOEC	Residential sludge	100 mg/l, 3 hours, Nominal
Algae	EC50	Green algae (Scenedesmus subspicatus)	0.95 mg/l, 72 hours
	NOEC	Green algae (Scenedesmus subspicatus)	0.62 mg/l, 72 hours
Crustacea	EC50	Water flea (Daphnia magna)	3.8 mg/l, 48 hours, Static test, OECD 202
	NOEC	Water flea (Daphnia magna)	1 mg/l, 48 hours, Static test
Fish	EC50	Rainbow trout (Juvenile Oncorhyncus mykiss)	33 mg/l, 96 hours, Static renewal test, OECD 203
	NOEC	Rainbow trout (Juvenile Oncorhyncus mykiss)	16 mg/l, 96 hours, Static renewal test
Microtox	MIC	Aspergillus flavus	1000 mg/l
		Azotobacter chroococcum	> 1000 mg/l
		Chaetomium globosum	1000 mg/l
		Nostoc sp.	1000 mg/l
		Pseudomonas fluorescens	> 1000 mg/l
Chronic			
Crustacea	LOEC	Water flea (Ceriodaphnia dubia)	> 0.4 mg/l, 7 days, 7 day static renewal, EPA 1002
	NOEC	Water flea (Ceriodaphnia dubia)	0.4 mg/l, 7 days
Fish	Growth test NOEC	Fathead minnow (Juvenile Pimephales promelas)	0.1 mg/l, 32 days, Static renewal test
Talc (CAS 14807-96-6)			
Aquatic			
Acute			
Fish	EC50	Zebra fish (Adult Brachydanio rerio)	> 100 g/l, 24 hours, Static renewal test

^{*} Estimates for product may be based on additional component data not shown.

12.2. Persistence and degradability

Persistence and degradability

Photolysis

Half-life (Photolysis-aqueous)

BUPROPION HYDROCHLORIDE 54 Hours

UV/visible spectrum wavelength

BUPROPION HYDROCHLORIDE 251 nm

Hydrolysis

Half-life (Hydrolysis-neutral)

BUPROPION HYDROCHLORIDE 16.7 Days

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

BUPROPION HYDROCHLORIDE 96 %, 14 days Modified Zahn-Wellens, Activated sludge

Percent degradation (Aerobic biodegradation-ready)

BUPROPION HYDROCHLORIDE 1.21 %, 14 days

12.3. Bioaccumulative potential

Material name: WELLBUTRIN TABLETS

Partition coefficient n-octanol/water (log Kow)

BUPROPION HYDROCHLORIDE 1.54

12.4. Mobility in soil

Adsorption

Sludge/biomass distribution coefficient - log Kd

BUPROPION HYDROCHLORIDE 1.79 Measured, pH 7

Soil/sediment sorption - log Koc

BUPROPION HYDROCHLORIDE 2.93 Calculated

Mobility in general

Volatility

Henry's law

BUPROPION HYDROCHLORIDE 0 atm m^3/mol. 25 C Estimated

Octanol/water distribution coefficient log DOW

BUPROPION HYDROCHLORIDE -0.6, pH 1.2 -0.91, pH 6 1.54, pH 7.4

12.5. Results of PBT

Not available.

and vPvB assessment

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

EU waste code The Waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Disposal methods/information Collect and reclaim or dispose in sealed containers at licensed waste disposal site. This material

> and its container must be disposed of as hazardous waste. Do not allow this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches with chemical or used container. Dispose of contents/container in accordance with local/regional/national/international

regulations.

Special precautions Dispose in accordance with all applicable regulations.

SECTION 14: Transport information

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine

environment. These materials may not be transported in bulk.

MARPOL73/78 and the IBC Code

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(1) Candidate List as currently published by ECHA

Not listed

Material name: WELLBUTRIN TABLETS

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at

work

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations The product is classified and labelled in accordance with EC directives or respective national laws.

This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

National regulations

Follow national regulation for work with chemical agents.

15.2. Chemical safety

assessment

No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations Not available.

References **GSK Hazard Determination**

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation

methods and test data, if available.

Full text of any statements or R-phrases and H-statements under Sections 2 to 15

R22 Harmful if swallowed.

R35 Causes severe burns. R36 Irritating to eyes.

R50 Very toxic to aquatic organisms.

R51/53 Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

R53 May cause long term adverse effects in the aquatic environment.

H302 Harmful if swallowed.

H314 Causes severe skin burns and eye damage.

H319 Causes serious eye irritation.

H331 Toxic if inhaled.

H335 May cause respiratory irritation. H351 Suspected of causing cancer. H400 Very toxic to aquatic life.

H410 Very toxic to aquatic life with long lasting effects.

Revision information None

Training information Follow training instructions when handling this material.

Disclaimer The information and recommendations in this safety data sheet are, to the best of our knowledge,

accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.